[Form 4] Staar Surgical Co Insider Trading Activity

Rhea-AI Filing Summary

STAAR Surgical Co. (STAA) – Form 4 insider filing dated June 20, 2025

Director Wei Jiang reported the receipt of 10,683 Restricted Stock Units (RSUs) on June 18, 2025 under the company’s annual non-employee director equity compensation program for the 2025-2026 term. Each RSU converts into one share of common stock upon vesting. The award vests in full on the earlier of June 18, 2026, or the 2026 Annual Meeting of Shareholders. The filing lists the RSUs at a conversion price of $0, and no shares were sold or disposed of. Following the grant, Ms. Jiang’s directly held derivative equity position totals 10,683 RSUs; no indirect ownership is disclosed.

Because the transaction is an automatic annual equity award and does not involve open-market purchases or sales, there is no immediate cash outflow or inflow for either the insider or the company. The filing primarily signals continued board-level alignment with shareholder interests but is not expected to be financially material to STAAR Surgical’s capitalization or share count.

Positive

• Director equity alignment: Award of 10,683 RSUs increases insider ownership incentives without cash cost, fostering shareholder alignment.

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine RSU grant to director; no shares sold, negligible balance-sheet impact, neutral for valuation.

The Form 4 documents a standard annual equity grant of 10,683 RSUs to non-employee director Wei Jiang. No derivatives were exercised, and no common shares were bought or sold. Vesting occurs in roughly one year or at the 2026 AGM, whichever comes first. Such grants modestly increase future share dilution (≈0.02% of the 48 million shares outstanding) and strengthen incentive alignment, but they have no immediate earnings, cash-flow, or governance ramifications. From a capital-markets perspective, the disclosure is procedural and neutral; it neither signals insider bullishness (no purchase) nor bearishness (no sale). I therefore classify the impact on STAA’s investment thesis as immaterial.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jiang Wei

(Last) (First) (Middle)

25510 COMMERCENTRE DRIVE

(Street)

LAKE FOREST CA 92630

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STAAR SURGICAL CO [ STAA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(1)	06/18/2025		A		10,683		(2)	(2)	Common Stock	10,683	$0	10,683	D

Explanation of Responses:

1. Each restricted stock unit (RSU) represents the right to receive one share of the Corporation's common stock upon vesting.

2. These equity awards vest in full on the earlier of June 18, 2026, or the Corporation's 2026 Annual Meeting of Shareholders.

Remarks:

This Form 4 reflects the equity awards granted to the Reporting Person on June 18, 2025, pursuant to the Corporation's annual non-employee director equity compensation program for the 2025-2026 term.

	/s/ Nathaniel Sisitsky as attorney-in-fact for Wei Jiang	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many RSUs did STAAR Surgical (STAA) grant to Director Wei Jiang?

The Form 4 shows a grant of 10,683 Restricted Stock Units.

When will the 10,683 RSUs awarded to Wei Jiang vest?

They vest in full on the earlier of June 18, 2026 or the company’s 2026 Annual Meeting of Shareholders.

Did the insider buy or sell any STAAR Surgical common shares?

No. The filing reports an RSU grant only; no open-market purchases or sales were made.

What is Wei Jiang’s total derivative equity position after the reported transaction?

Following the grant, she beneficially owns 10,683 RSUs and no indirect holdings were listed.

Is this Form 4 filing considered material to STAAR Surgical’s financials?

Given the small size relative to ~48 million shares outstanding, the transaction is not financially material to the company.